Tetrahydroxy stilbene glycoside (TSG) antagonizes Aβ-induced hippocampal neuron injury by suppressing mitochondrial dysfunction via Nrf2-dependent HO-1 pathway.

Amyloid-beta peptide (Aβ) ranks as a pivotal cause of Alzheimer's disease (AD), a common devastating dementia form in elderly. Recent research corroborated the beneficial roles of tetrahydroxystilbene glucoside (TSG) in alleviating the learning and memory of AD model and aged mice. Unfortunately, the underlying mechanism remains poorly elucidated. Here, treatment with non-toxic TSG dose-dependently antagonized Aβ-induced cytotoxic death in hippocampal neuronal cells by increasing cell viability and decreasing cell apoptosis. Furthermore, TSG also alleviated cell oxidative stress injury in response to Aβ by attenuating lactate dehydrogenase (LDH) release, ROS levels and MDA leakage. Importantly, TSG administration abrogated Aβ-triggered loss of mitochondrial membrane potential (Δym), release of cytochrome c from mitochondrial to cytosol, increase in caspase-3 activity and pro-apoptotic protein Bax, and decrease in Bcl-2 protein, indicating that TSG could rescue mitochondrial dysfunctions of neuron cells under adverse Aβ condition. Subsequently, TSG induced the activation of Nrf2-HO-1 pathway. Importantly, blocking this pathway by si-Nrf2 transfection or HO-1 antagonist ZnPP notably muted the cytoprotective effects of TSG on neuronal cell cytotoxic injury upon Aβ stimulation. Together, this research substantiated a new mechanism that TSG protectively antagonized Aβ-induced hippocampal neuronal cell damage by restoring mitochondrial function via Nrf2-HO-1 pathway, implying a promising candidate against neurodegenerative diseases including AD.